FDA accepts Sobi North America’s thrombocytopenia therapy sNDA
The US Food and Drug Administration (FDA) has accepted Sobi North America’s avatrombopag (DOPTELET) supplemental new drug application (sNDA) to…
Hematological Disorders
-
-
University of Birmingham identifies target to reduce GVHD risk
The University of Birmingham researchers have identified CD70 as a key target to reduce the risk of graft-versus-host disease (GVHD)…
-
Pfizer to withdraw sickle cell treatment OXBRYTA from market
Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease (SCD) from…
-
NHS England to offer Daiichi Sankyo’s quizartinib for AML
The National Health Service (NHS) England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML)…
-
MHLW accepts GSK’s multiple myeloma treatment NDA for review
Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK's new drug application (NDA) for Blenrep (belantamab…
-
MaxCyte and Kamau Therapeutics sign platform license agreement
MaxCyte, a company specialising in cell engineering technologies, has entered a strategic platform licence (SPL) agreement with Kamau Therapeutics, a…
-
FDA approves Amneal and Shilpa’s oncology product BORUZU
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals and Shilpa Medicare’s oncology product BORUZU for subcutaneous administration.…
-
Aptose Biosciences secures funds for AML treatment development
Aptose Biosciences has secured a loan of $10m through a facility agreement with Hanmi Pharmaceutical to advance the development of…
-
EC approves Roche’s monoclonal antibody PiaSky to treat PNH
The European Commission (EC) has approved Roche’s recycling monoclonal antibody, PiaSky (crovalimab), for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)…
-
FDA approves J&J’s multiple myeloma therapy
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s (J&J) DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for induction and consolidation…
